Sympathetic hyperactivity and its outcome in heart failure have been thoroughly investigated to determine the focus of pharmacologic approaches targeting the sympathetic nervous system in the treatment of this pathophysiological condition. On the other hand, therapeutic approaches aiming to protect the reduced cardiac parasympathetic function have not received much attention. The present study evaluated rats with chronic heart failure (six to seven weeks after coronary artery ligation) and the effects of an increased parasympathetic function by pyridostigmine (an acetylcholinesterase inhibitor) on the following aspects: arterial pressure (AP), heart rate (HR), baroreceptor and Bezold-Jarisch reflex, pulse interval (PI) and AP variability, cardiac sympathetic and parasympathetic tonus, intrinsic heart rate (i-HR) and cardiac function. Conscious rats with heart failure exhibited no change in HR, Bezold-Jarisch reflex, PI variability and cardiac sympathetic tonus. On the other hand, these animals presented hypotension and reduced baroreflex sensitivity, power in the low frequency (LF) band of the systolic AP spectrum, cardiac parasympathetic tonus and i-HR, while anesthetized rats exhibited reduced cardiac performance. Pyridostigmine prevented the attenuation of all the parameters examined, except basal AP and cardiac performance. In conclusion, the blockade of acetylcholinesterase with pyridostigmine was revealed to be an important pharmacological approach, which could be used to increase parasympathetic function and to improve a number of cardiocirculatory parameters in rats with heart failure.
Introduction
Congestive heart failure (CHF) is characterized by increased sympathetic (Liu and Zucker, 1999; Zucker, 2006; Schultz and Li, 2007; Zucker et al., 2012) and decreased parasympathetic activity (Bibevski and Dunlap, 1999; Dunlap et al., 2003) . The imbalance of the autonomic control is related to abnormalities in the cardiovascular reflexes, such as the attenuation of the baro-and cardiopulmonary sympathoinhibitory reflexes . In addition, the derangement of cardiovascular autonomic control involves an increase in the sympatho-excitatory reflexes, including the cardiac sympathetic afferent reflex and the chemoreflex (Zhu et al., 2002; Schultz and Li, 2007; Zucker et al., 2012) .
CHF produces an attenuation of the baroreflex in experimental animals (Dibner- Dunlap and Thames, 1989; Chen et al., 1991; Wang et al., 1991; Kar et al., 2011) and patients (Eckberg et al., 1971; Kassis et al., 1986; Kassis and Amtorp, 1987) . A decrease in Bezold-Jarisch reflex sensitivity has been documented in rats with myocardial infarction (Meyrelles et al., 1997; Andrade et al., 2007) . However, the sensitivity of this reflex was found to be augmented in rabbits with heart failure (Rocha et al., 2003) . Therefore, there is no consensus in the literature concerning the alteration of the Bezold-Jarisch reflex among different species.
Moreover, changes in cardiac function during CHF are related to prolonged sympathetic overactivity, which leads to cellular hypertrophy, apoptosis and alterations in contractile function (Singh et al., 2001) . Sympathetic overactivity has also been associated with an intrinsic heart rate (i-HR) decrease in patients (Jose and Taylor, 1969) and in rats (Du et al., 2007) as well as changes in the heart rate (HR) and arterial pressure (AP) variability in humans (La Rovere et al., 1998) and rats (Henze et al., 2008) .
Sympathetic hyperactivity and its management in CHF have been thoroughly investigated (Liu and Zucker, 1999; Zucker, 2006; Schultz and Li, 2007) and have led to, predominantly, the development of pharmacologic approaches targeting the sympathetic nervous system as part of the treatment of this pathophysiological condition (Bibevski and Dunlap, 2011) . On the other hand, therapeutic options to improve the cardiac parasympathetic function in heart failure have not received much attention in the literature. Nevertheless, previous studies have demonstrated that vagal stimulation prevented the pumping incapacity in patients with heart failure (De Ferrari et al., 2011) and reduced cardiac remodeling and arrhythmias, extending the long-term survival in animals models of CHF (Li et al., 2004; Zheng et al., 2005; Zhang et al., 2009) . Therefore, an increase in parasympathetic function seems to be a therapeutic alternative to prevent the outcomes of heart failure and improve cardiac performance.
A previous study has described that pyridostigmine bromide (PYR) elicited a parasympathetic neurotransmission increase by means of the inhibition of the enzymatic breakdown of acetylcholine at cholinergic receptor sites (Androne et al., 2003) . Additionally, PYR increased HR variability in normal rats (Soares et al., 2004) , healthy humans (Nobrega et al., 2001 ) and patients with heart failure (Behling et al., 2003) . In healthy human beings, PYR, given for one or two days, produced bradycardia (Dewland et al., 2007) without modifying cardiac function (De pontes et al., 1999; Androne et al., 2003) . In patients with heart failure, PYR improved HR recovery after exercise (Androne et al., 2003) , increased the pulse interval (PI) and reduced ventricular arrhythmia density (Behling et al., 2003) and ameliorated the autonomic and hemodynamic profile during dynamic exercise (Serra et al., 2009 ). These findings demonstrate that short-term administration of PYR has a modulatory effect on the cardiac sympathovagal balance in healthy and heart failure subjects, indicating that cardiovascular reflexes have a beneficial effect. Moreover, our laboratory has observed a protective effect of PYR on cardiac autonomic control and cardiac function 4 weeks after the onset of heart failure in rats (unpublished data). However, the effect of PYR on autonomic dysfunction, cardiovascular reflexes, HR and AP variability and heart performance has not been investigated in rats with chronic heart failure.
Therefore, the objective of the current study was to evaluate, in conscious rats with CHF, a more prolonged (six to seven weeks) effect of PYR on the following issues: basal MAP and HR, baroreflex and Bezold-Jarisch reflex, PI and systolic AP variability, cardiac autonomic control and i-HR. In addition, the current study also evaluated the cardiac function of anesthetized rats.
Methods
Experiments were performed on male Wistar rats (280-300 g) that were housed individually with free access to food and water and maintained on a 12:12 h light-dark cycle. All experimental procedures were carried out in accordance with the Guide for the Care and Use of Laboratory Animals 
Surgical procedures
Six to seven weeks before the experiments, the animals were anesthetized with an intraperitoneal injection of a mixture of ketamine (50 mg/kg, União Química Farmacêutica Nacional S/A, Embu-Guaçu, SP, Brazil) and xylazine (10 mg/kg, Hertape Calier Saúde animal S/A, Juatuba, MG, Brazil) and were endotracheally intubated and mechanically ventilated with a respirator (Harvard Apparatus Rodent Respirator, Model 680, Holliston, MA, USA). Heart failure was induced by a coronary artery ligation as previously described by Pfeffer et al. (1979) . Briefly, a left thoracotomy was performed through the fifth intercostal space, the pericardium was opened for heart exteriorization, and the left anterior descending coronary artery was ligated with a polyester suture (4-0 Ethicon, São José dos Campos, SP, Brazil). Next, the heart was brought back to the thoracic cavity, and the incision was sutured. The infarct size was confirmed by post-mortem examination, and only rats with an infarct size >40% of the left ventricular wall were considered. Sham-operated rats underwent a similar surgical procedure without coronary ligation. At the end of the surgery, the animals received an analgesic (flunixin meglumine, 2.5 mg/kg, sc) and were kept in the animal care of the Department Physiology of the School of Medicine of Ribeirão Preto (University of São Paulo). For the next three days following the surgical procedures, the animals were treated daily with an analgesic (flunixin meglumine, 2.5 mg/kg, sc). The animals were then housed for a period of six to seven weeks after the induction of the myocardial infarction (or sham surgery) until the data collection. During this period, the sham-operated rats and the rats with heart failure received tap water or PYR (Valeant Farmacêutica do Brasil Ltda, Campinas, SP, Brazil) dissolved in the drinking water (0.14 mg/mL). The dose of PYR (22 mg/kg/day) used in the current study was based on a previous study in our laboratory (unpublished data). Two days before the experiments, the rats were anesthetized with mixture of ketamine (50 mg/kg, União Química Farmacêutica Nacional S/A, Embu-Guaçu, SP, Brazil) and xylazine (10 mg/kg, Hertape Calier Saúde animal S/A, Juatuba, MG, Brazil), and polyethylene catheters were inserted into the left femoral artery and vein for the direct measurement of AP and the administration of the drugs, respectively. Both catheters were tunneled subcutaneously and exteriorized in the nape of the neck, and the surgical incision sites were sutured. The animals were maintained in individual cages during the recovery until the completion of the experimental protocol.
Experimental protocol
The animals were taken to the recording room thirty to forty minutes before the experiments, and the arterial catheter was connected to a pressure transducer (MLT0380/D, ADInstruments, Sydney, Australia), attached to an amplifier (ML110, ADInstruments, Sydney, Australia) and an A/D interface (Power Lab ML866, ADInstruments, Sydney, Australia). After taking the basal recording (2 kHz) of the AP for 30 min, the rats received, randomly, four doses (2, 4, 6 and 8 μg/kg, i.v.) of serotonin (5-HT, Sigma, St. Louis, MO, USA). Next, sodium nitroprusside (8 μg/kg, single bolus) and phenylephrine (250 μg/mL, at a rate of 87 μL/min) were intravenously administered in random order. The HR and AP were allowed to return to baseline levels between phenylephrine and nitroprusside administration. Finally, the rats were treated with atropine (2 μg/kg, iv) and propranolol (4 μg/kg, iv), given 15 min apart from each other. An additional group received the autonomic blockers in the inverse order (i.e., propranolol followed by atropine). On the next day, the rats were anesthetized with sodium pentobarbital (40 mg/kg ip, Rhobifarma Indústria Farmacêutica Ltda, Hortolândia, SP, Brazil) and had a Micro-Tip pressure catheter (SPR-407, Millar Instruments, Houston, TX, USA) inserted into the right carotid artery and advanced into the left ventricle (LV), as described previously (Pacher et al., 2008) , while the LV pressure was digitally (2 kHz) recorded. The LV end-diastolic pressure (LVEDP), maximal slope of systolic pressure increment (+ dP/dt max ) and diastolic pressure decrement (− dP/ dt max ) were calculated. After the recordings, while still under anesthesia, the heart and lungs were rapidly removed, rinsed in ice-cold 0.9% NaCl solution and weighed. The heart was collected, and the ventricles were cut transversally into two parts. The apex was fixed in phosphate-buffered 10% formalin and stained with picrosirius red, to measure the infarct size. Cardiac hypertrophy was evaluated by the cardiac weight index (heart weight/body weight ratio), while the degree of pulmonary edema was evaluated by the lung weight index (lung weight/body weight ratio).
Data analysis 2.3.1. PI and SAP variability
The analysis of PI and AP variability was performed from the basal recordings using a custom-made computer software (CardioSeries-v1.1, http://sites.google.com/site/cardioseries) developed in our laboratory. The standard deviation of the normal intervals of PI and systolic AP and the square root of the mean squared differences of successive PI (RMSSD) were calculated as indices of the overall variability of these parameters in the time domain. In addition, for the frequency domain analysis (spectral analysis) of systolic AP and PI, a series of basal values of these parameters were converted to data points every 100 ms using cubic spline interpolation and were divided into half-overlapping sequential sets of 512 data points (51.2 s). All of the segments were visually inspected, and the nonstationary data were discarded. A Hanning window was used to attenuate the side effects, and the spectrum of each segment was computed using a direct Fast Fourier Transform (FFT). The spectra were integrated in low (LF: 0.2-0.75 Hz) and high frequency bands (HF: 0.75-3.0 Hz). To assess the sympathovagal balance, the LF/HF ratio of the HR variability was calculated (Montano et al., 1994 ; Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology, 1996).
Bezold-Jarisch reflex
The Bezold-Jarisch reflex was evaluated by taking into account the maximal hypotensive (Δ MAP, mm Hg) and bradycardic (Δ HR, bpm) response elicited by the injection, at random order, of the four doses of 5-HT.
Spontaneous baroreflex sensitivity
The baroreflex control of the HR was assessed through the spontaneous oscillations in AP and PI by the sequence method. Ramps of progressive increases or decreases in systolic AP were automatically identified by the computer software HemoLab-ver.14.8 (http:// www.haraldstauss.com/HemoLab/HemoLab.php) in 8000 beat series from the basal recording period. The sequences, defined by ramps of at least four systolic AP values associated with parallel PI changes showing linear correlation coefficients higher than 0.8, were identified. Spontaneous BRS was calculated as the slope (ms/mm Hg) of the linear regression lines between the systolic AP and the subsequent PI intervals. The number of baroreflex sequences was corrected by the number of sequences/1000 heart beats.
Evoked baroreflex sensitivity
Evoked baroreflex (ms/mm Hg) sensitivity was assessed as the ratio of reflex PI lengthening to the phenylephrine-induced increase in the systolic AP and as the ratio of reflex PI shortening to the nitroprusside-induced fall in the systolic AP.
Cardiac autonomic tone and i-HR
The tachycardia obtained after atropine administration was used as an index of cardiac vagal tonus, whereas the bradycardia elicited by propranolol administration was used as a measure of cardiac sympathetic tonus. The HR values obtained after the double autonomic receptor blockade provided the i-HR, i.e., the HR remaining after the removal of adrenergic and cholinergic influence on the heart.
Morphological analysis
The hearts were cut transversely, fixed in phosphate-buffered 10% formalin and submitted to paraffin embedding. Each block was serially cut with a thickness of 7 μm from the midventricular surface. The sections were stained with picrosirius red to analyze the infarct size. The thickness of the left ventricular wall and the infarct size were measured using the public-domain software NIH Image J (developed by U.S. National Institutes of Health and available at http://rsb.info. nih.gov/nih-image/). The infarct size was calculated by dividing the length of the infarcted area by the total circumference of the LV and was expressed as a percentage.
Statistical analysis
The results are expressed as the mean ± standard error of the mean (SEM). The comparisons of the general characteristics of the animals studied (basal MAP, HR, sympathetic tonus, vagal tonus, i-HR and cardiac function parameters) were performed using a two-way ANOVA followed by the Tukey post-test. The differences were considered significant for P b 0.05.
Results
The infarcted area was similar between the rats treated or not, with PYR (Table 1) . Table 1 shows cross sections of representative hearts from the sham-operated and infarcted rats that received water or PYR. The sham-operated rats showed normal ventricular walls. On the other hand, a large scar (red color) was observed in rats with CHF. No differences were found in the body weight among all groups, while the heart and lung weight were greater in the rats with CHF as compared to the sham-operated counterparts (Table 1) .
Basal hemodynamics and cardiac function
The rats with CHF treated with water or PYR exhibited a lower basal MAP, but showed a similar HR (Table 1 ) when compared to the sham-operated counterparts. Moreover, the rats with CHF treated or not with PYR exhibited lower +dP/dt max and lower −dP/dt max but increased LVEDP as compared to the sham-operated controls (Table 2) .
Bezold-Jarisch reflex
No differences were found in either the hypotensive (Fig. 1, upper panel) or bradycardic responses (Fig. 1, lower panel) to the doses of 5-HT among all groups studied.
Evoked baroreflex sensitivity
The rats with heart failure receiving water exhibited lower sensitivity for the reflex bradycardia (Fig. 2 , left upper corner) but similar sensitivity for the reflex tachycardia (Fig. 2 , left lower corner) when compared with the sham-operated counterparts. However, PYR impaired the attenuation of the baroreflex sensitivity to reflex bradycardia in the rats with CHF.
Spontaneous baroreflex sensitivity
The spontaneous baroreflex gain, evaluated by the sequence method, in rats with CHF was markedly reduced in animals that received tap water. Treatment with PYR did not affect the gain of the spontaneous baroreflex in the sham-operated rats. Nevertheless, in the rats with heart failure, treatment with PYR prevented the impairment of the baroreflex gain (Fig. 2, right upper corner) . The number of Table 1 [Top] Cross sections of representative hearts, stained with picosirius red, from the four groups of rats studied.
[Bottom] Group data (mean ± SEM) of infarcted area (rats with CHF) as well as body weight, heart and lung weights in sham-operated control and rats with CHF chronically treated with PYR or water.
Sham-operated CHF
Water PYR Water PYR Infarcted area (%) --55 ± 1 57 ± 2 Body weight (g) 529 ± 20 519 ± 10 515 ± 10 510 ± 10 Heart weight (g) 1.39 ± 0.06 1.42 ± 0.05 1.80 ± 0.10 ⁎ 1.71 ± 0.07 ⁎ Lung weight (g) 2.7 ± 0.13 2.65 ± 0.08 3.33 ± 0.16 ⁎ 3.18 ± 0.19 ⁎ MAP (mm Hg) 110 ± 2 108 ± 3 95 ± 2 ⁎ 99 ± 2 ⁎ HR (bpm) 345 ± 10 337 ± 10 331 ± 9 353 ± 7 ⁎ P b 0.05 compared with sham-operated control counterparts. Bar = 3 mm.
baroreflex sequences was not different among all the groups studied (Fig. 2, right lower corner) . Table 3 shows the group data of PI and systolic AP variability in the rats with CHF and the sham-operated controls, treated with PYR or water. The time domain indices of PI and systolic AP variability did not show any differences among the groups. The spectral analysis of PI also did not show any differences among the groups. Nevertheless, the untreated (tap water) rats with CHF presented lower power in the LF band of systolic AP spectra as compared to the sham-operated control rats. Treatment with PYR prevented the attenuation of LF power of the AP spectra (Table 3 ).
PI and AP variability

Cardiac autonomic tone and i-HR
The rats with CHF receiving water or PYR showed similar bradycardic response caused by propranolol administration (cardiac sympathetic tonus) as compared to the sham-operated rats (Fig. 3) . On the other hand, the rats with CHF receiving water showed a smaller tachycardic response caused by atropine (cardiac parasympathetic tonus), while PYR prevented the reduction of the parasympathetic tonus in the rats with CHF as compared to the sham-operated controls (Fig. 3) . The combined administration of atropine and propranolol showed decreased i-HR in the rats with CHF that received tap water, while PYR impaired this attenuation (Fig. 3) .
Discussion
The results of the present study showed that PYR treatment was able to prevent, in chronic (six to seven weeks) myocardial-induced CHF, important cardiovascular derangements, such as the impairment of baroreflex sensitivity, AP variability profile, reduced cardiac vagal tonus and changes in the i-HR. On the other hand, PYR was not effective in avoiding the reduction of AP and cardiac performance (LVEDP, + dP/dt max and − dP/dt max ).
After myocardial infarction, the heart usually undergoes a process known as cardiac remodeling, which involves changes in the structure and function of the cardiomyocytes in the noninfarcted myocardium, leading to cardiac hypertrophy (Murdoch et al., 2006) . Additionally, the malfunction of the cardiac pump promotes the increase of pulmonary capillary pressure, which, undoubtedly, determines the pulmonary edema observed in CHF (Luz et al., 1975) . In the present study, we evaluated, indirectly, cardiac hypertrophy and pulmonary edema by the weight of the heart and lungs, respectively. Both the cardiac and lung indices were augmented in the rats with CHF, and PYR treatment did not affect any of these parameters.
As stated before, PYR failed to prevent the decrease in AP and did not improve the cardiac function indices (LVEDP, +dP/dt max and −dP/ dt max ). It is well to recall that the electrical stimulation of the vagus nerve also failed to prevent hypotension in rats with CHF (Li et al., 2004) . Therefore, the electrical or pharmacological (PYR) overactivation of the parasympathetic system failed to prevent the development of the hypotension that occurs in rats with chronic heart failure.
The Bezold-Jarisch reflex is triggered, experimentally, by the intravenous administration of 5-HT, which activates the cardiopulmonary receptors, particularly those conveying their action potentials through the vagal afferent C fibers producing hypotension, bradycardia and apnea (Krayer, 1961; Kashihara, 2009 ). Accordingly, 5-HT administration has been considered an important tool to investigate the Bezold-Jarisch reflex under normal and physiopathological conditions. In the current study, the hypotensive and bradycardic responses to increasing doses of 5-HT were unaltered in rats with CHF. However, other studies have shown an impairment of the Bezold-Jarisch reflex in infarcted rats (Meyrelles et al., 1997; Andrade et al., 2007) . A possible explanation for this discrepancy may be the size of the infarcted area (37% vs. 54% in the current study), providing a different degree of heart failure. However, the Bezold-Jarisch reflex sensitivity, evaluated by means of AP and HR changes after administration of ATP, was augmented in infarcted rabbits (Rocha et al., 2003) . Therefore, there is no consensus in the literature concerning the alteration of the Bezold-Jarisch reflex in experimental CHF induced by myocardial infarction.
A number of studies have demonstrated that the baroreflex plays an important role in cardiocirculatory control under normal conditions (Thrasher, 2005; Thomas, 2011) . In heart diseases, such as heart failure, a disorder of baroreflex function has been consistently documented Floras, 2009; Kar et al., 2011) . In line with the corresponding literature, the spontaneous baroreflex sensitivity (sequence analysis), as well as the reflex bradycardia induced by the increase in AP after phenylephrine administration, was impaired in rats with CHF. Nevertheless, PYR treatment was able to avoid this undesirable impairment in baroreflex sensitivity. Surprisingly, the reflex tachycardia to the sodium nitroprusside-induced decrease in AP was found to be similar among all the groups studied. Therefore, it can be hypothesized that −8961 ± 328 −9109 ± 913 −4850 ± 524 ⁎ −6007 ± 843 ⁎ LV-EDP (mm Hg) 6 ± 0.4 6 ± 1 12 ± 3 ⁎ 10 ± 3 ⁎ ⁎ P b 0.05 compared with sham-operated control counterparts. the blunted baroreflex sensitivity observed in the rats with chronic CHF may play a strong role by impairing the parasympathetic function. Previous studies have shown that the spectral analyses of HR and AP variability are valuable non-invasive tools, which can be used for estimating the relative autonomic modulation of the cardiovascular system (Pagani et al., 1986 ; Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology, 1996; Stauss, 2007) . In addition, it has been well documented that heart failure attenuates the HR variability, and this condition is considered to be a reliable predictor of cardiac mortality for cardiovascular diseases such as myocardial infarction or CHF (Ponikowski et al., 1997; La Rovere et al., 1998) . The time domain indices of overall PI and AP variability were not different among the rats with chronic CHF and the sham-operated controls. Nevertheless, the rats with CHF showed a marked reduction of LF power of the AP spectrum, while PYR avoided this outcome. Therefore, the current results indicate that the pharmacological improvement of the parasympathetic function during the development of CHF was effective in protecting against the changes in the AP variability profile.
The autonomic imbalance commonly experienced in CHF often leads to changes in HR variability in patients (Ponikowski et al., 1997; La Rovere et al., 1998) and experimental models of heart failure (Henze et al., 2008) . Nevertheless, in the present study, the time and frequency domain (spectral analysis) of the PI series did not show any difference between the sham-operated control and the rats with chronic CHF. The downregulation of the myocardial β-adrenoceptors (Gaemperli et al., 2010) and alterations of the cardiac sympathetic neurons, described in animals with heart failure (Liang, 2007) , might account for this discrepancy. Moreover, the current results are in line with the previous findings of Tobaldini et al. (2009) , who were also not able to detect consistent autonomic alterations in rats with heart failure, due to coronary artery ligation, when examining the HR variability. In addition, previous clinical study using norepinephrine spillover from the heart (Kingwell et al., 1994) , as well as an experimental study using recordings of cardiac sympathetic nerve activity (Jardine et al., 2002) , have indicated that a change in HR variability is not a good index of sympathetic activity. Therefore, these evidences may explain the lack of changes in sympathetic drive evaluated by means of the HR variability in the current study.
The pharmacological blockade of the autonomic receptor showed a decrease in cardiac vagal tonus in the rats with CHF. Dysfunction of the parasympathetic nervous system has been documented very early in the development of experimental heart failure (Bibevski and 3.9 ± 0.6 4.6 ± 0. 5.1 ± 1.3 4.4 ± 0.7 6.8 ± 1.7 7.7 ± 0.9 LF (nu) 12 ± 2 14 ± 1 8.5 ± 1.3 15 ± 4 HF (nu) 88 ± 2 86 ± 1 91.5 ± 1.3 85 ± 4 LF/HF 0.15 ± 0.03 0.18 ± 0.02 0.10 ± 0.02 0.24 ± 0.08 ⁎ P b 0.05 compared with sham-operated rats. # P b 0.05 compared with non-treated rats with CHF (treated with water). Dunlap, 1999; Dunlap et al., 2003; Bibevski and Dunlap, 2011) . In the present study, the attenuation of the parasympathetic tonus in animals with heart failure was prevented by PYR. Therefore, these findings provide support to the notion that the blockade of the acetylcholinesterase was effective in preserving the cardiac parasympathetic tonus after myocardial infarction. Surprisingly, the rats with CHF and their sham-operated counterparts showed a similar basal HR, while the blockade of the β-adrenoreceptors failed to reveal a cardiac sympathetic overactivity in the rats with CHF. The downregulation of the β-adrenoreceptor density (Gaemperli et al., 2010) and derangement of cardiac sympathetic neurons may also be mechanisms driving these results.
Another outcome of heart failure is the decrease of i-HR, which was confirmed in the current study. The attenuation of the i-HR has been well documented under clinical (Jose and Taylor, 1969) and experimental situations (Du et al., 2007) . A marked decrease of sodium channel expression in the sinoatrial node cells in CHF has been demonstrated (Du et al., 2007) . Thus, the inherent downregulation of sodium channel expression contributes to heart failure-induced sinoatrial node dysfunction (Du et al., 2007) and may be responsible for the decreased i-HR. In the current study, the i-HR was attenuated in the rats with heart failure, while PYRIDO prevented this alteration. Therefore, these findings suggest that inhibiting acetylcholinesterase and increasing the availability of acetylcholine in the synaptic cleft was quite effective in protecting the i-HR. However, further investigations are required to better understand the intrinsic mechanism of PYR on the sinoatrial node.
In conclusion, the current findings clearly showed that treatment with PYR is an important pharmacological approach to protect the physiological mechanisms during the development of heart failure six to seven weeks after coronary artery ligation. This finding is supported by the observation that PYR was remarkably efficient at preventing the attenuation of baroreflex sensitivity, a typical outcome of heart failure, which was evaluated by spontaneous and evoked baroreflex sensitivity assessment. In addition, PYR treatment avoided changes in i-HR and the cardiovascular autonomic control, as examined by AP variability and cardiac parasympathetic tonus. In contrast, the data from the current study were not able to show a beneficial effect of PYR on cardiac function in the time frame of six to seven weeks of heart failure in rats.
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